MIM LesionID™ Pro: Recently 510(k) cleared by the U.S. FDA, this AI-powered software automates whole-body tumor burden analysis, reducing the need for manual lesion segmentation, physiologic uptake removal, or multi-image registration while enabling fast access to quantitative insights.
Omni Legend: GE HealthCare’s fastest-selling PET/CT platform, now with more than 500 installations worldwide.[vii] Its high-sensitivity design supports faster scans,[viii] improved image quality and enhanced lesion detectability.[ix] Omni Legend also includes Precision DL deep learning image processing.
Ad Statistics
Times Displayed: 0
Times Visited: 0 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money.
StarGuide: A digital SPECT/CT platform featuring 12 CZT detectors and optimized for certain theranostic procedures, enabling high-quality 3D imaging, short scan times and quantitation.
MINItrace Magni:[x] A compact cyclotron solution designed to simplify onsite production of PET tracers and radiometals, including Gallium-68, helping expand radiopharmaceutical access and support more localized production and personalized care delivery.
Radiopharmaceuticals and imaging agents –
Flyrcado: A PET imaging agent that helps doctors evaluate myocardial ischemia and infarction in people with known or suspected coronary artery disease, including during exercise stress tests.
DaTscan™ (ioflupane I‑123 injection): A proven neurological diagnostic radiopharmaceutical – celebrating 25 years in the global market – to visualize striatal dopamine transporters assisting in the evaluation of patients with suspected Parkinsonian syndromes (PSs) and suspected dementia with Lewy bodies (DLB).
Cerianna™ (fluoroestradiol F 18 injection): A PET radiopharmaceutical used to detect estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.
Vizamyl: A PET imaging agent used to estimate amyloid beta neuritic plaque density in adults with cognitive impairment to support evaluation of Alzheimer’s disease and other causes of cognitive decline, and to help inform selection of patients for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products.
Together, these imaging technologies and agents are designed to support more scalable, data-driven and personalized nuclear medicine workflows across care pathways.
Preparing the ecosystem for the next decade of growth
As nuclear medicine adoption continues to grow, healthcare systems are increasingly focused on the operational requirements needed to support broader clinical use – including infrastructure, workflow standardization, radiopharmaceutical access and scalable decision support. [xi]
